Free Trial
→ Financial legend: “This is bad, really bad...” (From Weiss Ratings) (Ad)tc pixel
NASDAQ:CLRB

Cellectar Biosciences Q3 2026 Earnings Date & Estimates

Cellectar Biosciences logo
$1.29 -0.02 (-1.68%)
As of 12:51 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Cellectar Biosciences is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026, before market opens. The conference call is scheduled for 8:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Cellectar Biosciences in Q3 2026

Cellectar Biosciences is expected to post earnings of -$0.5565 per share on revenue of $17 million. In the same quarter a year earlier Cellectar Biosciences reported -$1.41 per share. Cellectar Biosciences last reported on August 13, 2026, posting -$0.57 per share and missing the -$0.52 consensus estimate. Cellectar Biosciences has beaten the consensus EPS estimate in 6 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.5565
Expected Revenue
$17 million
Prior-Year EPS
-$1.41

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.57 (Missed by -$0.05)
EPS Beat Rate
6 of last 8 quarters

Prepare for the Q3 2026 Call

Cellectar Biosciences Q3 2026 Earnings FAQ

Cellectar Biosciences (NASDAQ:CLRB) is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Cellectar Biosciences' Q3 2026 earnings conference call is scheduled for Tuesday, November 10, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Cellectar Biosciences to post earnings of -$0.5565 per share for Q3 2026.

The consensus revenue estimate for Cellectar Biosciences is $17 million for Q3 2026.

Cellectar Biosciences Earnings Headlines

Cellectar Biosciences to Present Three Posters Highlighting Durable Clinical Activity of Iopofosine I 131 in Waldenström Macroglobulinemia at the American Society of ...
 |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/cellectar-biosciences-present-three-posters-140000064.html
Cellectar Biosciences to Present Three Posters Highlighting Durable Clinical Activity of Iopofosine I 131 in Waldenström Macroglobulinemia at the American Society of Hematology Annual Meeting and Exposition
 |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/04/3395373/29076/en/cellectar-biosciences-to-present-three-posters-highlighting-durable-clinical-activity-of-iopofosine-i-131-in-waldenstr%c3%b6m-macroglobulinemia-at-the-american-society-of-hematology-ann.html
Last call for your free 0DTE report
The 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, protect it. This report normally sells for 29.97, but it's available as a free download for a limited time.tc pixel
November 4 at 1:00 AM  |  Profits Run (Ad)
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Tuesday, November 10, 2026
November 2 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/02/3393103/29076/en/cellectar-biosciences-to-report-third-quarter-financial-results-and-host-a-conference-call-on-tuesday-november-10-2026.html
Cellectar Reports 8-Year Complete Response With Iopofosine I 131; Stock Up
October 28, 2026  |  rttnews.comhttps://www.rttnews.com/3703559/cellectar-reports-8-year-complete-response-with-iopofosine-i-131-stock-up.aspx
Cellectar Biosciences Reports Durable Complete Response in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131
October 27, 2026  |  quiverquant.comQ
See More Cellectar Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cellectar Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cellectar Biosciences and other key companies, straight to your email.

About Cellectar Biosciences

Cellectar Biosciences (NASDAQ:CLRB) (NASDAQ: CLRB) is a clinical-stage biopharmaceutical company focused on developing targeted radiotherapeutics and oncology treatments. Its technology platform uses phospholipid ether compounds, which are designed to preferentially accumulate in cancer cells and other diseased tissues while limiting exposure to healthy tissue.

The company’s leading product candidate is iopofosine I 131, also known as CLR 131, a small-molecule radiopharmaceutical being studied for the treatment of hematologic malignancies, including relapsed or refractory multiple myeloma and certain types of lymphoma. Cellectar is also advancing additional phospholipid ether-based compounds and programs intended to support targeted imaging, drug delivery and treatment of cancer.

Founded in 2003 and headquartered in Madison, Wisconsin, Cellectar conducts its research and clinical development activities primarily in the United States, while its investigational programs may involve international clinical and regulatory activities. James Caruso serves as the company’s president and chief executive officer.

View Cellectar Biosciences Profile
Earnings Tools